Dr. Khalid Ahmed Al-Anazi is currently working as Consultant and Chairman, Department of Adult Hematology and Hematopoietic Stem Cell Transplantation, King Fahad Specialist Hospital (KFSH) in Dammam, Saudi Arabia.
He graduated from the college of medicine, King Saud University (KSU) in Riyadh, in the year 1986. After passing his Boards in Internal Medicine, he trained in clinical hematology and hematopoietic stem cell transplant at King’s College Hospital, University of London, U.K. He has 4 year experience in internal medicine and 26 year experience in adult clinical hematology and hematopoietic stem cell transplantation (HSCT) at the Armed Forces Hospital, King Faisal Specialist Hospital and Research Center (KFSH&RC), King Khalid University Hospital (KKUH) and the College of Medicine, KSU in Riyadh and KFSH in Dammam, Saudi Arabia.
He received the award of the best teacher in the Department of Medicine, at the College of Medicine and KKUH in Riyadh in the year 2014. During his work at KFSH&RC in Riyadh and KFSH in Dammam, he was heavily involved in Hemato-Oncology and HSCT and he contributed to the success and achievements at both institutions in addition to the establishment of the HSCT unit at KFSH in Dammam in the year 2010. He has 70 publications including retrospective studies, review articles, book chapters and electronic books and he is a reviewer for 21 international medical journals. He is the Editor-in-Chief of the Journal of Stem Cell Biology and Transplantation in addition to being an Associate Editor of 26 other medical journals in HSCT, hematology, cancer and infectious diseases.
The available therapeutic modalities for diabetes mellitus (DM) include: diet and lifestyle modifications, oral hypoglycemic agents, insulin injections and pancreatic islet cell transplantation. The efficacy of autologous hematopoietic stem cell transplantation (HSCT) in type 1 DM was first reported in the year 2007. Since then, several studies have confirmed not only the safety, but also the efficacy of autologous HSCT in both types of DM.
High-dose immunosuppressive therapy combined with infusion of hematopoietic stem cells (HSCs) downregulate the autoreactive T-cells, renew the immune system, improve the immune regulatory networks and ultimately induce insulin independence in type 1 DM. The increased C-peptide and the decreased HbA1C levels encountered in animal and human trials have shown that stem cell therapies can offer an effective treatment for type 1 and possibly type 2 DM. Recently, clinical trials in humans have utilized various forms of stem cell therapies including: HSCs, umbilical cord blood stem cells, embryonic stem cells as well as mesenchymal stem cells.
Our group at King Fahad Specialist Hospital in Dammam, Saudi Arabia has recently published the first world report of curing insulin dependent DM in a patient who received an autologous HSCT in order to control his multiple myeloma in March 2013.